Dr. Reddy's Laboratories Limited American Depositary Shares (RDY) Stock Price
RDYStock
$13.07+29.85%52W
Market Cap$10.89B
P/E24.27x
PEG Ratio1.71
Div yield0.71%
Beta0.02
RDY Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-9.64%
Price vs S&P 500 (4W)5.38%
PEG Ratio1.71
VGM Score52.14
P/E Ratio (Annual)24.27x
Indicated Dividend Yield (Annual)0.71%
RDY Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.36
3.36
2.87
2.84
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
RDYDr. Reddy's Laboratories Limited American Depositary Shares | D | C | B | 3.1x | -0.9% | 61.4% | 16.5% | $13.07 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Dr. Reddy's Laboratories Limited American Depositary Shares
Dr. Reddy's is one of the world's largest generic pharmaceutical manufacturers with diversified operations spanning generic drugs, injectables, and active pharmaceutical ingredients. The company generates approximately half its generics revenue from North America, with additional significant contributions from India (20%), Russia (10%), and other international markets; injectables represent 25% of North American sales. The company maintains top-five market positions in key Indian therapeutic areas including oncology and gastroenterology through its branded generics portfolio. Its API division manufactures 150+ active ingredients supplied across more than 75 countries.